MA54809A - Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique - Google Patents
Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chroniqueInfo
- Publication number
- MA54809A MA54809A MA054809A MA54809A MA54809A MA 54809 A MA54809 A MA 54809A MA 054809 A MA054809 A MA 054809A MA 54809 A MA54809 A MA 54809A MA 54809 A MA54809 A MA 54809A
- Authority
- MA
- Morocco
- Prior art keywords
- macitentan
- treatment
- pharmaceutical composition
- pulmonary hypertension
- thromboembolic pulmonary
- Prior art date
Links
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 title 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title 1
- 229960001039 macitentan Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000002815 pulmonary hypertension Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019051874 | 2019-01-25 | ||
| EP2019060152 | 2019-04-18 | ||
| EP2019066495 | 2019-06-21 | ||
| EP2019067187 | 2019-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54809A true MA54809A (fr) | 2022-04-20 |
Family
ID=69177170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054809A MA54809A (fr) | 2019-01-25 | 2020-01-24 | Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220096474A1 (fr) |
| EP (1) | EP3914253A1 (fr) |
| JP (1) | JP2022522612A (fr) |
| KR (1) | KR20210120024A (fr) |
| CN (1) | CN113329751A (fr) |
| AU (1) | AU2020211014A1 (fr) |
| BR (1) | BR112021014499A2 (fr) |
| CA (1) | CA3127271A1 (fr) |
| CL (1) | CL2021001933A1 (fr) |
| CO (1) | CO2021011046A2 (fr) |
| IL (1) | IL284988A (fr) |
| JO (1) | JOP20210198A1 (fr) |
| MA (1) | MA54809A (fr) |
| MX (1) | MX2021008574A (fr) |
| PH (1) | PH12021551728A1 (fr) |
| SG (1) | SG11202106312SA (fr) |
| TW (1) | TW202042818A (fr) |
| WO (1) | WO2020152308A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897646B1 (fr) | 2018-12-21 | 2024-05-22 | Actelion Pharmaceuticals Ltd | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| US20240423980A1 (en) * | 2023-06-23 | 2024-12-26 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods of preventing a venous thromboembolic event |
| CN120267675A (zh) * | 2025-04-16 | 2025-07-08 | 江苏济茗医药有限公司 | 一种阿普昔腾坦和利尿剂的组合物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1693372A1 (fr) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Nouveaux sulfamides et leur utilisation comme antagoniste du récepteur d'endotheline |
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| MX350011B (es) | 2008-08-13 | 2017-08-22 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas que contienen macitentan. |
| IL266518B2 (en) | 2016-11-10 | 2026-05-01 | Arena Pharm Inc | Methods for treating pulmonary hypertension with combinations of relinfag and other substances |
| WO2018153925A1 (fr) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Compositions pharmaceutiques stables comprenant du macitentan |
| UA126122C2 (uk) | 2017-02-27 | 2022-08-17 | Ідорсія Фармасьютікалз Лтд | Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном |
| EP3897646B1 (fr) | 2018-12-21 | 2024-05-22 | Actelion Pharmaceuticals Ltd | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
| JOP20220126A1 (ar) | 2019-11-26 | 2023-01-30 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية لعلاج أمراض الأوعية الدموية الرئوية و/أو خلل وظيفي في القلب لمرضى فونتان المُخفّف |
-
2020
- 2020-01-22 TW TW109102673A patent/TW202042818A/zh unknown
- 2020-01-24 MA MA054809A patent/MA54809A/fr unknown
- 2020-01-24 PH PH1/2021/551728A patent/PH12021551728A1/en unknown
- 2020-01-24 BR BR112021014499-4A patent/BR112021014499A2/pt not_active IP Right Cessation
- 2020-01-24 CA CA3127271A patent/CA3127271A1/fr active Pending
- 2020-01-24 JP JP2021542147A patent/JP2022522612A/ja active Pending
- 2020-01-24 SG SG11202106312SA patent/SG11202106312SA/en unknown
- 2020-01-24 KR KR1020217026476A patent/KR20210120024A/ko not_active Withdrawn
- 2020-01-24 MX MX2021008574A patent/MX2021008574A/es unknown
- 2020-01-24 AU AU2020211014A patent/AU2020211014A1/en not_active Abandoned
- 2020-01-24 CN CN202080010613.7A patent/CN113329751A/zh active Pending
- 2020-01-24 WO PCT/EP2020/051707 patent/WO2020152308A1/fr not_active Ceased
- 2020-01-24 JO JOP/2021/0198A patent/JOP20210198A1/ar unknown
- 2020-01-24 EP EP20701195.8A patent/EP3914253A1/fr not_active Withdrawn
- 2020-01-24 US US17/425,576 patent/US20220096474A1/en not_active Abandoned
-
2021
- 2021-07-20 IL IL284988A patent/IL284988A/en unknown
- 2021-07-22 CL CL2021001933A patent/CL2021001933A1/es unknown
- 2021-08-23 CO CONC2021/0011046A patent/CO2021011046A2/es unknown
-
2022
- 2022-05-04 US US17/736,434 patent/US11612600B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021014499A2 (pt) | 2021-09-28 |
| US11612600B2 (en) | 2023-03-28 |
| CN113329751A (zh) | 2021-08-31 |
| SG11202106312SA (en) | 2021-07-29 |
| WO2020152308A1 (fr) | 2020-07-30 |
| JOP20210198A1 (ar) | 2023-01-30 |
| IL284988A (en) | 2021-09-30 |
| JP2022522612A (ja) | 2022-04-20 |
| CL2021001933A1 (es) | 2022-04-08 |
| KR20210120024A (ko) | 2021-10-06 |
| AU2020211014A1 (en) | 2021-09-16 |
| CO2021011046A2 (es) | 2022-01-17 |
| CA3127271A1 (fr) | 2020-07-30 |
| PH12021551728A1 (en) | 2022-04-04 |
| MX2021008574A (es) | 2021-08-11 |
| US20220096474A1 (en) | 2022-03-31 |
| TW202042818A (zh) | 2020-12-01 |
| US20220331319A1 (en) | 2022-10-20 |
| EP3914253A1 (fr) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1005I2 (fr) | Compositions comprenant des polypeptides actriia pour leur utilisation dans le traitement de l'hypertension pulmonaire | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3755804A4 (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| EP3645044A4 (fr) | Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, membre a5, pour le traitement du glaucome | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3634426A4 (fr) | Compositions pour le traitement d'une fibrose | |
| EP3445352A4 (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme | |
| EP3877418A4 (fr) | Schéma posologique d'anticorps anti-tigit pour le traitement du cancer | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3810091A4 (fr) | Méthodes et compositions pour le traitement de l'hypertension pulmonaire | |
| EP3911329A4 (fr) | Composition pour la prévention ou le traitement d'une maladie du foie métabolique | |
| EP3758716A4 (fr) | Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium | |
| IL284988A (en) | A pharmaceutical preparation containing mesitantan for the treatment of chronic thromboembolic pulmonary hypertension | |
| EP3768274A4 (fr) | Composition destinée à être utilisée dans le traitement d'états provoqués par une déficience en calcium | |
| EP3522983A4 (fr) | Compositions à base de cromolyne pour le traitement d'une fibrose pulmonaire | |
| EP3827831A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de la stéatohépatite non alcoolique | |
| EP4181915A4 (fr) | Compositions pour le traitement de l'obésité | |
| EP3795170C0 (fr) | Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne | |
| EP4021480A4 (fr) | Peptides pour le traitement de troubles rénaux | |
| EP3858351A4 (fr) | Composition pharmaceutique pour le traitement de la fibrose | |
| EP4340881A4 (fr) | Anticorps pour le traitement d'alpha-synucléinopathies | |
| EP3979817A4 (fr) | Composition pour l'inhibition de transporteur de prostaglandines et applications thérapeutiques associées |